Active, not recruitingPHASE1, PHASE2NCT03386513
Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN
Studying Blastic plasmacytoid dendritic cell neoplasm
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- AbbVie
- Principal Investigator
- ABBVIE INC.AbbVie
- Intervention
- IMGN632(drug)
- Enrollment
- 179 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2018 – 2026
Study locations (28)
- Banner Health MD Anderson Cancer Center, Gilbert, Arizona, United States
- City of Hope Medical Center, Duarte, California, United States
- UCLA, Los Angeles, California, United States
- Stanford, Stanford, California, United States
- Moffitt Cancer Center, Tampa, Florida, United States
- University of Maryland Medical Center, Baltimore, Maryland, United States
- Dana-Farber Cancer Institute, Boston, Massachusetts, United States
- Roswell Park Cancer Institute, Buffalo, New York, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Novant Health Cancer Institute Hematology, Charlotte, North Carolina, United States
- Duke Cancer Institute, Durham, North Carolina, United States
- Novant Health Cancer Institute Hematology - Forsyth, Winston-Salem, North Carolina, United States
- Baylor Scott & White University Medical Center, Dallas, Texas, United States
- MD Anderson Cancer Center, Houston, Texas, United States
- Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, Washington, United States
- +13 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03386513 on ClinicalTrials.govOther trials for Blastic plasmacytoid dendritic cell neoplasm
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07523555Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic MalignanciesBeijing Biotech
- RECRUITINGPHASE1, PHASE2NCT06006403Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell NeoplasmChongqing Precision Biotech Co., Ltd
- RECRUITINGNCT05430971Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International RegistryImmune Oncology Research Institute
- RECRUITINGPHASE2NCT04216524Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell NeoplasmM.D. Anderson Cancer Center
- RECRUITINGPHASE1NCT03113643SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)Dana-Farber Cancer Institute
See all trials for Blastic plasmacytoid dendritic cell neoplasm →